PCN19 Beyond a Binary Endpoint: Longitudinal and Individual Symptom Analyses from the Simplify-1 Study Demonstrate Clinically Comparable Symptomatic Benefit of Momelotinib to Ruxolitinib in JAK Inhibitor Naive Myelofibrosis Patients
Jun 1, 2021, 00:00 AM
10.1016/j.jval.2021.04.111
https://www.valueinhealthjournal.com/article/S1098-3015(21)00328-4/fulltext
Section Title :
Section Order :
10596
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)00328-4&doi=10.1016/j.jval.2021.04.111